Medical Condition News

RSS

Gut microbiota plays a causal role in development of diabetes and NAFLD

Exciting new data presented today at the International Liver Congress 2012 shows the gut microbiota's causal role in the development of diabetes and non-alcoholic fatty liver disease (NAFLD), independent of obesity.

19 Apr 2012

Two studies show true impact of liver disease across Europe

Two studies presented at the International Liver Congress- 2012 show the true impact that liver disease has across Europe. One highlights the financial cost of liver disease to the community and the second highlights the high mortality rates associated with cirrhosis.

19 Apr 2012

Johns Hopkins Heart and Vascular Institute to open new building on April 29

Patients with heart and vascular disease will be cared for in spacious, state-of-the-art private rooms when Johns Hopkins opens its new hospital building to the first patients on April 29. The Johns Hopkins Heart and Vascular Institute occupies a major part of the 1.6 million-square-foot facility, which has 560 all-private patient rooms with private baths and 33 expansive operating rooms.

19 Apr 2012

Researchers describe how they combine two pieces of technology to create neuroprosthesis

An artificial connection between the brain and muscles can restore complex hand movements in monkeys following paralysis, according to a study funded by the National Institutes of Health.

19 Apr 2012

NSCLC patients with EGFR mutations benefit from erlotinib-first regimen

Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

19 Apr 2012

New studies on personalized lung cancer treatment presented at 3rd ELCC

Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.

19 Apr 2012

ARVO to host presentation of results from two clinical trials on neovascular AMD

ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

19 Apr 2012

New techniques show promise in detecting early-stage lung cancer

New techniques for identifying lung cancer earlier -including a new type of chest screening, a nanotech 'nose' and a method to examine the cells of the cheek-- are showing substantial promise, according to presentations at the 3rd European Lung Cancer Conference (ELCC) in Geneva.

19 Apr 2012

Physical exercise, meditation can change brains for the better

Practices like physical exercise, certain forms of psychological counseling and meditation can all change brains for the better, and these changes can be measured with the tools of modern neuroscience, according to a review article now online at Nature Neuroscience.

19 Apr 2012

Magnetic nanochain detonates chemo barrage inside tumors

Medicine-toting nanochains slip into tumors and explode a chemotherapy drug into hard-to-reach cores of cancer, engineers and scientists at Case Western Reserve University report.

19 Apr 2012

ESTRO 31 and the World Congress of Brachytherapy to take place from May 9-13

ESTRO 31 and the World Congress of Brachytherapy will combine to feature new research results in clinical and basic radiobiology, physics and brachytherapy, presented by top doctors and scientists from all over the world working together for the benefit of cancer patients.

19 Apr 2012

Perampanel drug may significantly reduce seizure frequency

A new type of anti-epilepsy medication that selectively targets proteins in the brain that control excitability may significantly reduce seizure frequency in people whose recurrent seizures have been resistant to even the latest medications, new Johns Hopkins-led research suggests.

19 Apr 2012

New passive vaccine reverses dangerous symptoms of cocaine overdose

Scientists are reporting development and successful testing in laboratory mice of a substance that shows promise for becoming the first antidote for cocaine toxicity in humans. According to a report in ACS' journal Molecular Pharmaceutics, the new so-called "passive vaccine" reversed the motor impairment, seizures and other dangerous symptoms of a cocaine overdose, which claims thousands of lives each year among users of the illicit drug.

19 Apr 2012

First specific antidote for cocaine toxicity

Scientists at The Scripps Research Institute have shown that an injectable solution can protect mice from an otherwise lethal overdose of cocaine. The findings could lead to human clinical trials of a treatment designed to reverse the effects of cocaine in case of emergency. Cocaine is involved in more than 400,000 emergency-room visits and about 5,000 overdose deaths each year in the United States.

19 Apr 2012

Half of young adult tobacco smokers also have used marijuana in the last 30 days

Half of young adult tobacco smokers also have smoked marijuana in the last 30 days, according to a recent Facebook-based survey conducted by UCSF researchers, indicating a greater prevalence of marijuana and tobacco co-use among smokers age 18-25 than previously reported.

19 Apr 2012

Regular physical activity may decrease risk of AD even in very old adults

Daily physical activity may reduce the risk of Alzheimer's disease and cognitive decline, even in people over the age of 80, according to a new study by neurological researchers from Rush University Medical Center that will be published in the online issue of Neurology, the medical journal of the American Academy of Neurology on April 18.

19 Apr 2012

GSK, Epizyme and Constellation to develop next generation of epigenetic drugs for cancer

Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.

19 Apr 2012

UCSF scientists solve mystery of how selective hearing works

The longstanding mystery of how selective hearing works - how people can tune in to a single speaker while tuning out their crowded, noisy environs - is solved this week in the journal Nature by two scientists from the University of California, San Francisco.

19 Apr 2012

Ecstasy and speed-using grade ten students more likely to develop depression

A five year study conducted with thousands of local teenagers by University of Montreal researchers reveals that those who used speed (meth/ampthetamine) or ecstasy (MDMA) at fifteen or sixteen years of age were significantly more likely to suffer elevated depressive symptoms the following year. "Our findings are consistent with other human and animal studies that suggest long-term negative influences of synthetic drug use," said co-author Fr-d-ric N. Bri-re of the School Environment Research Group at the University of Montreal.

19 Apr 2012

Merck wins New Jersey FOSAMAX litigation

Merck, known outside the United States and Canada as MSD, today said a state court jury in New Jersey found in its favor in the Sessner v. Merck case, rejecting the claims of a woman who blamed her jaw-related problems on her FOSAMAX use.

19 Apr 2012